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PURPOSE: Lipid nanocapsules (LNC) entrapping lipophilic complexes of (188)Re
((188)Re(S(3)CPh)(2)(S(2)CPh) [(188)Re-SSS]) were investigated as a novel
radiopharmaceutical carrier for internal radiation therapy of malignant gliomas. The
present study was designed to evaluate the efficacy of intra-cerebral administration
of (188)Re-SSS LNC by means of convection-enhanced delivery (CED) on a 9L rat
brain tumour model. METHODS: Female Fischer rats with 9L glioma were treated
with a single injection of (188)Re-SSS LNC by CED 6days after cell implantation.
Rats were put into random groups according to the dose infused: 12, 10, 8 and 3Gy
in comparison with blank LNC, perrhenate solution (4Gy) and non-treated animals.
The radionuclide brain retention level was evaluated by measuring (188)Re
elimination in faeces and urine over 72h after the CED injection. The therapeutic
effect of (188)Re-SSS LNC was assessed based on animal survival. RESULTS: CED of
(188)Re perrhenate solution resulted in rapid drug clearance with a brain T (1/2) of
7h. In contrast, when administered in LNC, (188)Re tissue retention was greatly
prolonged, with only 10% of the injected dose being eliminated at 72h. Rat median
survival was significantly improved for the group treated with 8Gy (188)Re-SSS LNC
compared to the control group and blank LNC-treated animals. The increase in the
median survival time was about 80% compared to the control group; 33% of the
animals were long-term survivors. The dose of 8Gy proved to be a very effective dose,
between toxic (10-12Gy) and ineffective (3-4Gy) doses. CONCLUSIONS: These
findings show that CED of (188)Re-loaded LNC is a safe and potent anti-tumour
system for treating malignant gliomas. Our data are the first to show the in vivo
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